Multispecific antigens binding fragments and multispecific antibodies
The invention relates to multispecific antibody constructs comprising Fab fragments having mutations at the interface of the CH1 and CL domains, said mutations preventing heavy chain/light chain mispairing.
1. A multispecific antibody construct comprising at least two Fab fragments with different CH1 and CL domains, wherein each Fab fragment recognizes a different epitope of interest, and wherein at least one Fab fragment is a mutated Fab fragment that comprises:
the VH and VL domains of an antibody recognizing an epitope of interest;
a CH1 domain which is derived from the CH1 domain of a human immunoglobulin by substitution of the leucine residue at position 143 of said CH1 domain with a glutamine residue and substitution of the serine residue at position 188 of said CH1 domain with a valine residue; and
a CL domain of the kappa type which is derived from the CL-kappa domain of a human immunoglobulin by substitution of the valine residue at position 133 of said CL-kappa domain with a threonine residue and substitution of the serine residue at position 176 of said CL-kappa domain with a valine residue; wherein the position numbers used for the CH1 and CL-kappa domains refer to Kabat numbering.
2. The multispecific antibody construct of claim 1 , comprising
a) at least one mutated Fab fragment consisting of:
i) the VH and VL domains of an antibody recognizing an epitope of interest;
ii) a CH1 domain of a human immunoglobulin comprising substitution of the leucine residue at position 143 of said CH1 domain with a glutamine residue and substitution of the serine residue at position 188 of said CH1 domain with a valine residue; and
iii) a CL-kappa domain of a human immunoglobulin comprising substitution of the valine residue at position 133 of said CL-kappa domain with a threonine residue and substitution of the serine residue at position 176 of said CL-kappa domain with a valine residue; and
b) at least one mutated Fab fragment consisting of:
i) the VH and VL domains of an antibody recognizing an epitope of interest;
ii) a CH1 domain of a human immunoglobulin comprising substitution of the threonine residue at position 192 of said CH1 domain with a glutamic acid residue; and
iii) a CL-kappa domain of a human immunoglobulin comprising substitution of the asparagine residue at position 137 of said CL domain with a lysine residue and substitution of the serine residue at position 114 of said CL domain with an alanine residue
wherein the position numbers used for the CH1 and CL domains refer to Kabat numbering.
3. A therapeutic composition comprising a multispecific antibody construct of claim 1 and a pharmaceutically acceptable vehicle.